Zentek Ltd (ZTEK) — Titan Protect Analysis

ZTEK

Zentek Ltd

Healthcare · ·

$0.52

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$57M

Total market value of the company

Trailing P/E

N/A

Forward P/E

N/A

Based on estimated future earnings — lower means cheaper

Rev Growth

+73.1%

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-56.6%

Return on equity — how efficiently it uses shareholder money

Analyst Target

N/A

Recommendation

NONE

Consensus view from ? analysts covering this stock

About Zentek Ltd

Zentek Ltd., together with its subsidiaries, engages in the research and development of graphene and related nanomaterials in Canada. The company develops graphene-based antimicrobial coatings under the ZenGUARD brand, surgical masks, HVAC filters, personal protective equipment, rapid detection point of care diagnostics tests, and pharmaceutical products based on graphene-based compounds. It also developing aptamers and rapid detection; and graphene oxide synthesis and graphene synthesis product

https://www.zentek.com

Country: Canada Employees: 18 Industry: Medical Instruments & Supplies

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

0.053

Positive but modest risk-adjusted returns

Kelly Fraction

-0.0838

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.394

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-30.1%

Historical annualised return based on price data

Max Drawdown

-76.4%

Largest peak-to-trough decline — the worst it has been

HMM State

CRISIS

Elevated risk detected — extreme caution warranted

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.31

Very low correlation to market moves

52W High

$1.55

66% below the year high

52W Low

$0.40

30% above the year low

Avg Volume

126,614

Average daily shares traded — higher means easier to buy and sell

Short Ratio

1.2

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.06

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

15.41

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

50.5%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-4,155.2%

Profit from core operations before interest and tax

Free Cash Flow

$-1,694,322

Negative — the business is spending more than it generates

Revenue (TTM)

$942,877

Total revenue over the last 12 months

Net Income

$-8,081,361

Loss-making — spending exceeds revenue after all costs

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go